Program Overview

The 3rd Annual Global Summit on Genitourinary Malignancies focuses on the clinical and practical changes that will occur over the next five years in prostate cancer, renal cell carcinoma and bladder cancer. The program is formatted to foster discussion and debate on the evolution of treatment approaches to genitourinary malignancies featuring didactic lectures, panel discussions and case presentations over individual patient issues and new approaches designed to overcome these challenges.

Presentations will be given by leading experts in the field of genitourinary malignancies, who will offer further insight during question-and-answer sessions. In addition to these leading experts, fellows and junior faculty will have the opportunity to present and discuss their abstracts at an evening poster reception. The Summit assembles translational researchers, clinical researchers, and key community oncologists to address and discuss the challenges of this rapidly developing area of oncology.

Summit Chairs

petrylak

Daniel P. Petrylak, MD, completed his medical degree at Case Western Reserve University School of medicine, and completed his internal medicine residency at Albert Einstein College of Medicine/Jacobi Medical center and fellowship at Memorial Sloan Kettering Cancer Center. He is currently Director of Genitourinary Oncology, and Co-Director of the Signal Transduction Program at Yale University Cancer Center.


Daniel Petrylak, MD


Summit Chair Person

Yale University

New Haven, CT

ryan

Charles J. Ryan, MD, is the Director of the Hematology, Oncology, and Transplantation Division in theDepartment of Medicine at the University of Minnesota, Minneapolis. He also serves as the AssociateDirector for Clinical Research in the Masonic Cancer Center and holds the B.J. Kennedy Chair in ClinicalMedical Oncology. He is the Leader of the Advanced Prostate Cancer Cadre in the Alliance for Clinical Trials in Oncology, a national clinical trials group.


Charles Ryan, MD


Summit Chair Person

University of Minnesota

Minneapolis, MN

sartor

Oliver Sartor, MD, is a medical oncologist with a special focus on prostate cancer over the past 28 years. He is currently the Laborde Professor for Cancer Research, Medical Director of the Tulane Cancer Center, and Assistant Dean for Oncology at Tulane University School of Medicine in New Orleans, LA. He has published over 350 peer review publications and has over 20,000 citations. He has lectured widely, giving lectures on prostate cancer in 34 countries.


Oliver Sartor, MD


Summit Chair Person

Tulane Medical School

New Orleans, LA



view all speakers

PEDRO BARATA, MD, MSC


Assistant Professor of Medicine
Internal Medicine/Hematology-Oncology Section/Genitourinary Cancers

Tulane Cancer Center

New Orleans, LA

pedrobarata

MATTHEW R. COOPERBERG, MD, MPH


Professor of Urology and Epidemiology & Biostatistics Associate Chair, Clinical Research, Department of Urology


Helen Diller Family Chair in Urology University of California, San Francisco

San Francisco, CA

matthewcooperberg

ANNA FERRARI, MD


Professor of Medicine, Oncology

Albert Einstein College of Medicine Montefiore Medical Center

Bronx, NY

annaferrari

TERENCE FRIEDLANDER, MD


Associate Professor of Medicine

UCSF Medical Center

San Francisco, CA

terencefriedlander

PETROS GRIVAS, MD, PHD


Associate Professor Clinical Director of Genitourinary Cancers Program

Fred Hutchinson Cancer Research Center University of Washington

Seattle, WA

petrosgrivas

HANS HAMMERS, MD, PHD


Associate Professor

The University of Texas Southwestern

Medical Center
Dallas, TX

Celestia Higano, MD, FACP


Professor of Medicine

University of Washington

Seattle, WA

celestiahigano

Eric Jonasch, MD


Professor of Medicine

University of Texas MD Anderson Cancer Center

Houston, TX

ericjonasch

STACEY KENFIELD, SCD


Associate Professor of Urology Helen Diller Family Chair in Population Science for Urologic Cancer Department of Urology

University of California, San Francisco

San Francisco, CA

staceykenfield.jpg

Joseph Kim, MD


Assistant Professor

Yale University

New Haven, CT

josephkim

VADIM S. KOSHKIN, MD


Assistant Professor

University of California, San Francisco

San Francisco, CA

vadimkoshkin

BENJAMIN MAUGHAN, MD, PHARMD


Assistant Professor, Division of Medical Oncology Huntsman Cancer Institute

Unviersity of Utah

Salt Lake City, UT

benjaminmaughan

ARPIT RAO, MD


ASSISTANT PROFESSOR, DIVISION OF HEMATOLOGY, ONCOLOGY AND TRANSPLANTATION CHAIR, M HEALTH/FAIRVIEW ONCOLOGY QUALITY AND SAFETY COMMITTEE

University of Minnesota Masonic Cancer Center

Minneapolis, MN

arpitrao

ABHISHEK SOLANKI, MD


Assistant Professor Director of Clinical Research & Quality Medical Director Department of Radiation Oncology

Stritch School of Medicine, Loyola University

Maywood, IL

abhisheksolanki

SRIKALA SRIDHAR, MD, MSC, FRCPC


Associate Professor

Princess Margaret Cancer Center

Toronto, Ontario, Canada

srikalasridhar

WALTER STADLER, MD


Fred C. Buffett Professor Departments of Medicine & Surgery,Dean for Clinical Research Deputy Director, Comprehensive Cancer Center

The University of Chicago Medicine

Chicago, IL

walterstadler


Nimira Alimohamed, MD, FRCPC


Clinical Associate Professor

Department of Oncology Cumming School of Medicine
University of Calgary

Calgary, Alberta, Canada

Pasquale Benedetto, MD


Professor

Sylvester Comprehensive Cancer Center
University of Miami

Miami, FL

Hamid Emamekhoo, MD


Assistant Professor

University of Wisconsin Carbone Cancer Center University of Wisconsin School of Medicine and Public Health

Madison, WI

Andrew Hong, MD


Instructor of Pediatrics

Harvard Medical School Dana-Farber Cancer Institute

Boston, MA

Rohit Jain, MD, MPH


Assistant Member, Department of Genitourinary Oncology

Moffitt Cancer Center

Tampa, FL

ANIL KAPOOR, MD, FRCSC


Director, Urologic Cancer Centre for Research & Innovation Head, Genito-Urinary Oncology Program Juravinski Cancer Centre, Professor of Surgery (Urology) and Oncology

McMaster University Hamilton,

Ontario, Canada

DEEPAK KILARI, MD


Assistant Professor

Medical College of Wisconsin

Milwaukee, WI

Neyssa Marina, MD


Executive Medical Director

Synthorx

La Jolla, CA

Alicia K. Morgans, MD, MPH


Associate Professor of Medicine

Northwestern University Feinberg School of Medicine

Chicago, IL

Ron Peck, MD


Chief Medical Officer

Arvinas

New Haven, CT

William Tester, MD, FACP


Clinical Professor of Medical Oncology Medical Director of Outpatient Operations Jefferson Sidney Kimmel Cancer Center

Thomas Jefferson University

Philadelphia, PA

Ulka Vaishampayan, MD


Chair, Division of Solid Tumor Oncology Director of Phase I Therapeutics Karmanos Cancer Institute Charles Martin Endowed Chair Professor of Oncology

Wayne State University

Detroit, MI

Christopher Weight, MD


Director, Urologic Oncology Fellowship Associate Professor , Department of Urology


University of Minnesota

Minneapolis, MN

Alexander Wyatt, PhD


Senior Research Scientist Vancouver Prostate Centre Assistant Professor, Department of Urologic Sciences

University of British Columbia

Vancouver, British Columbia, Canada

Haris Zahoor, MD


Assistant Professor of Clinical Medicine Keck School of Medicine

University of Southern California

Los Angeles, CA

Summit Agenda

Download Schedule
  • 5:45 PM Welcome and Introductions

  • Keynote Address

    6:00 PM GU Malignancies: Perspectives and a Peer Into the Future

    Eric Jonasch

  • Setting The Stage

    Moderator: Charles Ryan

    6:30 PM Can We Make Prostate Cancer a Chronic Disease?

    TBD

    6:45 PMCan We Cure Metastatic Renal Cell Carcinoma?

    Hans Hammers

    7:00 PM How Do We Integrate New Therapies into the Treatment of Bladder Cancer?

    Walter Stadler

    7:15 PM Next Steps for Immunotherapy in GU Malignancies

    Srikala Sridhar

    7:30 PM Using Genomics to Select Patients for Organ Preservation

    William Tester

    7:45 PMDiscussion

    8:00 PMAdjourn to Welcome Reception

  • 5:45 PM Welcome and Introductions

  • Keynote Address

    6:00 PM GU Malignancies: Perspectives and a Peer Into the Future

  • Setting The Stage

    6:30 PM Can We Make Prostate Cancer a Chronic Disease?

    6:45 PMCan We Cure Metastatic Renal Cell Carcinoma?

    7:00 PM How Do We Integrate New Therapies into the Treatment of Bladder Cancer?

    Walter Stadler

    7:15 PM Next Steps for Immunotherapy in GU Malignancies

    Srikala Sridhar

    7:30 PM Using Genomics to Select Patients for Organ Preservation

    William Tester

    7:45 PMDiscussion

    8:00 PMAdjourn to Welcome Reception

  • 6:00 AM Breakfast

  • Advances In Imaging And Surgery

    Moderator: Oliver Sartor

    7:00 AM Non-Invasive Monitoring of Urothelial Cancers

    TBD

    7:15 AM New Perspectives in PET Imaging in Prostate Cancer

    Oliver Sartor

    7:30 AM Deep Learning in Kidney Cancer Imaging: How AI Will Revolutionize Kidney Cancer Care

    Christopher Weight

    7:45 AM Discussion

    8:00 AM The Role of Genomic Risk in Prostate Cancer Surveillance

    Matthew Cooperberg

    8:15 AM The Role of Nephrectomy in the Age of Modern Therapeutics

    Ulka Vaishampayan

    8:30 AM Discussion

    8:45 AM Break

  • Progress In Renal Cell Carcinoma Therapies

    Moderator: Charles Ryan

    9:05 AM How to Choose First-line Therapy for RCC

    Haris Zahoor

    9:20 AM Anti-tumor Activity of Small Molecule Glutaminase Inhibitors

    TBD

    9:35 AM Next-generation Immunotherapy in RCC

    Hans Hammers

    9:50 AM Discussion

  • Novel Targets And Approaches For GU Malignances

    Moderator: Daniel Petrylak

    10:05 AM Novel Immunoconjugates in Bladder Cancer

    Srikala Sridhar

    10:20 AM PSMA Targeted Therapies in Advanced Prostate Cancer

    Oliver Sartor

    10:35 AMUsing Synthetic Biology to Design and Manufacture Optimized Medicines for the Treatment of Cancer

    Neyssa Marina

    10:50 AM Discussion

    11:10 AM Targeting the DNA Repair Pathway

    Charles Ryan

    11:25 AM Development of an Androgen Receptor PROTAC® in Prostate Cancer

    Ron Peck

    11:40 AM Targeting PTEN Loss and PI3K in Prostate Cancer Therapeutics

    Pedro Barata

    11:55 AM Discussion

    12:15 PM Adjourn

  • Debating Technology: Is There A Role For Chemotherapy In Metastatic Cspc?

    Moderator: Charles Ryan

    5:00 PM Hormonal Therapy: The Future of mCSPC Treatment

    TBD

    5:10 PM Chemotherapy is Not Dead in Prostate Cancer

    TBD

    5:20 PMDiscussion

  • The Spectrum Of Metastatic Disease In Prostate Cancer

    Moderator: Oliver Sartor

    5:40 PM Defining Oligometastatic Disease in Prostate Cancer

    TBD

    5:55 PM The Role of Treating the Primary in Metastatic Prostate Cancer

    Matthew Cooperberg

    6:10 PMStereotactic Body Radiation Therapy in Oligometastatic Cancer

    Abhishek Solanki

    6:25 PMDiscussion

    6:40 PMBreak

  • Targeted Therapy In Bladder Cancer

    Moderator: Daniel Petrylak

    7:00 PM Neoadjuvant Therapy for Muscle Invasive Bladder Cancer

    Deepak Kilari

    7:15 PM Targeting the IL2 Pathway to Engage the Immune Response

    TBD

    7:30 PMTargeting FGFR in Bladder Cancer

    Petros Grivas

    7:50 PM Emerging Agent Showcase: Mirati Therapeutics

    TBD

    8:05 PM Discussion

    8:30 PM Adjourn To Poster Reception

  • 6:00 AM Breakfast

  • Setting The Stage

    7:00 AM The Era of Personalized Therapy for GU Tumors

    TBD

  • The Role Of Immuno And Radiotherapy

    Moderator: Charles Ryan

    7:15 AMVEGFR TKI and PD-1/PD-L1 Combinations for First-line RCC

    Hamid Emamekhoo

    7:30 AMImmunotherapy in Prostate Cancer

    TBD

    7:45 AMImmune Checkpoint Inhibitors and Cytokine Combinations in GU Malignancies

    Rohit Jain

    8:00 AMCombination Immunotherapy and Radiotherapy in Bladder Cancer

    Abhishek Solanki

    8:15 AMPSMA-Targeting Radioligand Therapy in Prostate Cancer

    Vadim Koshkin

    8:30 AMDiscussion

    8:50 AMBreak

  • Learning from Genomics and Biomarkers

    Moderator: Daniel Petrylak

    9:10 AM The Relationship Between the Microbiome and GU Malignancies

    Charles Ryan

    9:25 AM Molecular Assessments of Resistance to Hormonal Therapies in Prostate Cancer

    Benjamin Maughan

    9:40 AM Epigenetic Modulation of Antiandrogen Resistance

    Anna Ferrari

    9:55 AM Discussion

    10:10 AM Assessing Biomarkers for Bladder Cancer

    Petros Grivas

    10:25 AM Non-invasive Genotyping and Stratification using Cell-free DNA

    Alexander Wyatt

    10:40 AM Utility of Circulating Tumor Cells in GU Malignancies

    Terence Friedlander

    10:55 AM Discussion

  • Targeting The Androgen Receptor In Prostate Cancer

    Moderator: Oliver Sartor

    11:10 AM Evolution of Androgen Receptor Alterations During Sequential Inhibition

    Alexander Wyatt

    11:35 AM Role of AR-V7 in Sequencing Therapeutic Agents for CRPC

    TBD

    11:50 AMStrategies for Targeting the Androgen Receptor Axis in Prostate Cancer

    Ulka Vaishampayan

    12:05 PM Apalutamide: New Approaches and Future Directions

    TBD

    12:20 PM Discussion

    12:40 PM Adjourn

  • Debating Technology: Is There A Role For Immune Therapy For Urothelial Patients With Visceral Disease?

    Moderator: Daniel Petrylak

    5:00 PMThe Promise of Immunotherapy in Urothelial Cancer

    TBD

    5:15 PMFighting Urothelial Cancer without Immunotherapy

    TBD

    5:30 PMDiscussion

  • Addressing Therapeutic Challenges In GU Malignancies

    Moderator: Oliver Sartor

    5:50 PM The Potential of High-dose Testosterone: Re-sensitizing Patients to Hormonal Therapy

    Pedro Barata

    6:05 PM Addressing Neuroendocine Differentation in Prostate Cancer

    TBD

    6:20 PMClinical Development of PARP Inhibitors for Genitourinary Cancers

    TBD

    6:35 PMFuture of mTOR Inhibitors in GU Malignancies

    Joseph Kim

    6:50 PMDiscussion

  • Quality Of Life And Outcome Considerations For GU Malignancies

    Moderator: Charles Ryan

    7:10 PMWomen and Bladder Cancer: Unique Needs and Special Strategies

    Alicia Morgans

    7:25 PM Diet and Lifestyle Modifications in Prostate Cancer

    Stacey Kenfield

    7:40 PMNew Perspectives in Non-metastatic CRPC

    Celestia Higano

    7:55 PM Quality of Life as an Outcome in Prostate Cancer

    Alicia Morgans

    8:10 PMDiscussion

    8:30 PMAdjourn

  • Oral Abstracts

    7:00 AMOral Abstract 1

    7:15 AM Oral Abstract 2

    7:30 AMOral Abstract 3

    7:45 AMOral Abstract 4

    8:00 AMOral Abstract 5

    8:15 AMOral Abstract 6

    8:30 AMMEETING CONCLUDES

Attendance Benefits

  • Networking opportunities with GU oncology leaders
  • Post-meeting access to video presentations
  • Participate in discussion and debate surrounding the field of GU oncology
  • Daily breakfast, evening receptions with refreshments


Travel Details

North America Map
banff fairmont hotel

Hotel

  • The 3rd Annual Global Summit on Genitourinary Malignancies will be held at the Fairmont Chateau Banff Springs
  • OMI room block is closed but attendees can register through the room block link until the Fairmont is at capacity

Transfer

  • Transfer time between YYC and the Fairmont Banff Springs: 2 hours
  • OMI recommends using the Banff Airporter for transfer at a 20% discounted rate with promo code “OMI”
  • Discounted rate: 114 CAD/person (roundtrip)

Fall Activities in Banff

  • Scenic hiking
  • Gondala rides
  • Biking
  • Village shopping
  • Tour Lake Louise
  • Wildlife tours
  • Horseback riding

Dava Oncology – three divisions, one focus

dava oncology logo
omi logo
one-oncology logo

Contact Us